Clusterin Human ELISA
Clusterin (Apolippoprotein J; SP-40,40; TRPM-2; SGP-2; pADHC-9; CLJ; T64; GP III; XIP8) is a highly conserved disulfide-linked secreted heterodimeric glycoprotein of 75-80 kDa but truncated forms targeted to the nucleus have also been identified.
The protein is constitutively secreted by a number of cell types including epithelial and neuronal cells and is a major protein in physiological fluids including plasma, milk, urine, cerebrospinal fluid and semen. Due to its wide breath of tissue distribution many diverse physiological functions have been attributed to Clusterin including sperm maturation, membrane recycling, lipid transportation, tissue remodelling, complement inhibition and cell-cell or cell-substratum interactions. Moreover, it was proposed that Clusterin functions as an extracellular chaperon that stabilizes stressed proteins in a folding-competent state, and that the protein is involved in programmed cell death. Another defining prominent function of Clusterin is its induction in many severe physiological disturbances states including kidney degenerative diseases, prostate and vesicle carcinogenesis, ovarian cancer and several neurodegenerative conditions (Alzheimer’s disease).
A recent study demonstrates that serum Clusterin level increases significantly in diabetic type II patients and in patients with developing coronary heart disease, or myocardial infarction. These data raise the possibility that elevated Clusterin levels in serum may represent a strong indication of vascular damage.
In patients with systemic lupus erythematosus (SLE), reduced serum Clusterin levels correlated inversely with disease activity. Lowered Clusterin levels could be involved in the pathogeneses of SLE on account of decreased protective effects.
Another interesting observation obtained in rat model suggests that measurement of urinary Clusterin levels may be a useful clinical marker for the severity of renal tubular damage. Furthermore, urinary Clusterin may also help to differentiate between tubular and glomerular forms of proteinuria.
Areas of investigation:
Coronary heart diseases, Myocardial infarction, Neurodegenerative diseases, Kidney degenerative disease, Renal tubular damage
Type
Sandwich ELISA, Biotin-labelled antibody
Applications
Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine, Cerebrospinal fluid
Sample Requirements
5 µl/well
Storage/Expiration
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
5–160 ng/ml
Limit of Detection
0.5 ng/ml
Intra-assay (Within-Run)
n = 8; CV = 6.2%
Inter-assay (Run-to-Run)
n = 8; CV = 7.8%
Spiking Recovery
103,20%
Dilutation Linearity
99,30%
Crossreactivity
bovine Non-detectable
cat Non-detectable
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
mouse Non-detectable
pig Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable
chicken Not tested
human Yes
monkey Yes (recommended dilution 1:1500)
– Aguilar-Mahecha A, Cantin C, O’Connor-McCourt M, Nantel A, Basik M. Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker. Proteome Sci. 2009;7:15
– Banfi C, Parolari A, Brioschi M, Barcella S, Loardi C, Centenaro C, Alamanni F, Mussoni L, Tremoli E. Proteomic analysis of plasma from patients undergoing coronary artery bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin alpha1-antichymotrypsin. J Proteome Res. 2010 May 7;9 (5):2347-57
– Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Sep 20;28 (27):4247-54
– Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res. 2009 Jan 15;15 (2):708-13
– Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L. Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res. 2011 Jan 7;10 (1):211-20
– Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007 Jul;6 (7):2833-40
– Dukic L, Simundic AM, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, Diamandis EP. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem. 2016 Feb;49 (3):213-8
– Flehmig G, Scholz M, Kloting N, Fasshauer M, Tonjes A, Stumvoll M, Youn BS, Bluher M. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One. 2014;9 (6):e99785
– Garcia-Rodriguez S, Arias-Santiago S, Perandres-Lopez R, Orgaz-Molina J, Castellote L, Buendia-Eisman A, Ruiz JC, Naranjo R, Navarro P, Sancho J, Zubiaur M. Decreased plasma levels of clusterin in patients with psoriasis. Actas Dermosifiliogr. 2013 Jul-Aug;104 (6):497-503
– Holzer M, Trieb M, Konya V, Wadsack C, Heinemann A, Marsche G. Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta. 2013 Sep;1831 (9):1442-8
– Kwon HS, Kim TB, Lee YS, Jeong SH, Bae YJ, Moon KA, Bang BR, Moon HB, Cho YS. Clusterin expression level correlates with increased oxidative stress in asthmatics. Ann Allergy Asthma Immunol. 2014 Mar;112 (3):217-21
– Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology. 2010 Feb;75 (2):454-9
– Nafee AM, Pasha HF, El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral-related hepatocellular carcinoma. Clin Biochem. 2012 Sep;45 (13-14):1070-4
– Riaz MA, Stammler A, Borgers M, Konrad L. Clusterin signals via ApoER2/VLDLR and induces meiosis of male germ cells. Am J Transl Res. 2017 Mar 15;9(3):1266-1276
– Rithidech KN, Honikel L, Milazzo M, Madigan D, Troxell R, Krupp LB. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult Scler. 2009 Apr;15 (4):455-64
– Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17 (17):5765-73
– Schlatzer D, Maahs DM, Chance MR, Dazard JE, Li X, Hazlett F, Rewers M, Snell-Bergeon JK. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care. 2012 Mar;35 (3):549-55
– Seferovic MD, Chen S, Pinto DM, Gupta MB. Altered liver secretion of vascular regulatory proteins in hypoxic pregnancies stimulate angiogenesis in vitro. J Proteome Res. 2011 Feb 15; – Solichova P, Karpisek M, Ochmanova R, Hanulova Z, Humenanska V, Stejskal D, Bartek J. Urinary clusterin concentrations–a possible marker of nephropathy? Pilot study. Biomed Pap Med Fac Univ Palack. 2007 Dec;151 (2):233-6
– Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma . 53(4):343-6 (2006)
– Stejskal D, Lacnak B, Karpisek M, Kaminek M. Our experiences with measurement of new potential biomarkers in the diagnosis of latent forms of myocardial ischemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub . Dec;150(2):239-44 (2006)
– Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O’Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010 Jul;67 (7):739-48
– Vareka I, Stejskal D, Varekova R, Burianova K, Hnatek J. Changes in clusterin serum concentration levels in oncologic patients during the course of Spa therapy – a pilot study. Biomed Pap Med Fac Univ Palack. 2009; 153:117-120;
– Wang Y, Liu YH, Mai SJ, He LJ, Liao YJ, Deng HX, Guan XY, Zeng YX, Kung HF, Xie D. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis . Journal of Gastroenterology an. 25 (2010) 1123–1128;
– Zhang F, Sha J, Wood TG, Galindo CL, Garner HR, Burkart MF, Suarez G, Sierra JC, Agar SL, Peterson JW, Chopra AK. Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA). Cell Signal. 2008 May;20 (5):844-61
– Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW, Chopra AK. Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal. 2009 Jul;21 (7):1085-99
– Zurek J, Fedora M. Changes in the serumlevels of clusterin in childrenwith sepsis. Pediatriapolska. 2013;88:6-13